EP0920331A1 - Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin - Google Patents
Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricinInfo
- Publication number
- EP0920331A1 EP0920331A1 EP97935939A EP97935939A EP0920331A1 EP 0920331 A1 EP0920331 A1 EP 0920331A1 EP 97935939 A EP97935939 A EP 97935939A EP 97935939 A EP97935939 A EP 97935939A EP 0920331 A1 EP0920331 A1 EP 0920331A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- lactoferrin
- lactoferricin
- treatment
- pharmaceutical composition
- prevention
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000010445 Lactoferrin Human genes 0.000 title claims abstract description 85
- 108010063045 Lactoferrin Proteins 0.000 title claims abstract description 85
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 title claims abstract description 83
- 229940078795 lactoferrin Drugs 0.000 title claims abstract description 82
- 235000021242 lactoferrin Nutrition 0.000 title claims abstract description 82
- 101800004361 Lactoferricin-B Proteins 0.000 title claims abstract description 40
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 title claims abstract description 39
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 24
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 23
- 230000002265 prevention Effects 0.000 title claims abstract description 23
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 21
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 27
- 208000019206 urinary tract infection Diseases 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 10
- 206010009887 colitis Diseases 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000013350 formula milk Nutrition 0.000 claims abstract description 5
- 241000283690 Bos taurus Species 0.000 claims description 7
- 239000000413 hydrolysate Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 16
- 102000050459 human LTF Human genes 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 229940100601 interleukin-6 Drugs 0.000 description 13
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 11
- 229940072440 bovine lactoferrin Drugs 0.000 description 11
- 239000002158 endotoxin Substances 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 8
- 102000000589 Interleukin-1 Human genes 0.000 description 7
- 108010002352 Interleukin-1 Proteins 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000020256 human milk Nutrition 0.000 description 5
- 210000004251 human milk Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000000110 microvilli Anatomy 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 4
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000002939 deleterious effect Effects 0.000 description 4
- 108010071397 lactoferrin receptors Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001635 urinary tract Anatomy 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000004941 influx Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229940096397 interleukin-8 Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- BFVQTKQTUCQRPI-YYEZTRBPSA-N LPS with O-antigen Chemical compound O([C@@H]1[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]5[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O5)O)O4)O)[C@@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)NC(C)=O)O2)NC(C)=O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)OC([C@@H]1O)O[C@H]1[C@H](O)[C@@H]([C@@H](O)COC2[C@H]([C@@H](O)[C@H](OP(O)(O)=O)[C@@H]([C@@H](O)CO)O2)O)OC([C@H]1O)O[C@H]1[C@H](OP(O)(=O)OP(O)(=O)OCCN)[C@@H]([C@@H](O)CO)OC([C@H]1O)O[C@H]1[C@H](O[C@]2(O[C@@H]([C@@H](O)[C@H](O[C@]3(O[C@@H]([C@@H](O)[C@H](OP(O)(=O)OCCN)C3)[C@@H](O)CO)C(O)=O)C2)[C@@H](O)CO)C(O)=O)C[C@](O[C@@H]1[C@@H](O)CO)(OC[C@H]1O[C@@H](OC[C@@H]2[C@H]([C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O2)O)[C@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@H]([C@@H]1OP(O)(O)=O)OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)C(O)=O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O BFVQTKQTUCQRPI-YYEZTRBPSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000003375 selectivity assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a pharmaceutical composition comprising lactoferrin and/or lactoferricin for treatment and/or prevention of infections, inflamma- tions and/or tumours, to the use of lactoferrin and lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammations and tumours, and to a method for treatment and/or prevention of infections, inflammations and/or tu- mours comprising administration of lactoferrin and/or lactoferricin.
- human milk in several ways is anti- inflammatory.
- Goldman et al. pointed out that human milk is poor in initiators and mediators of inflammation but rich in anti-inflammatory agents (see Goldman A. S., et al., Anti-inflammatory properties of human milk, Acta Paediatr. Scand. 75 : 689-695, ' 1986) .
- Human milk contains several soluble anti-infective components, such as specific secretory IgA (SIgA) antibodies and non-specific components, including lactoferrin (LF) (see e.g. Hanson L. A., et al., Protective factors in milk and the development of the immune system, Pediatrics 75:172-176, 1983) .
- SIgA specific secretory IgA
- LF lactoferrin
- Lactoferrin is a single chain metalbinding glycopro- tein with a molecular weight of 77 kd. It occurs in three isoforms: LF- ⁇ , LF- ⁇ , and LF- ⁇ . These three variants have the same physical, chemical and antigenic characteris- tics, but differ in their functional properties.
- the iron-binding lactoferrin is also present in specific granules of polymorphonuclear leucocytes and in other exocrine secretions than milk such as saliva, tears and bronchial mucus, as well as cervical secretion, amni- otic fluid, decidua, and trophoblasts (see e.g. Montreuil J., et al., Isolement d'une lactosiderophiline du lait de appropriate, CR Acad. Sci. Paris 250 D: 1736-37, 1960; Montreuil J., et al., Preparation et proprietes de la lactosiderophiline (lactotransferrine) du fait de an, Biochim. Biophys.
- Lactoferrin an ironbinding protein neutrophilic leucocytes, J. Exp. Med. 130:643-656, 1969). Lactoferrin is associated with host defense at mucosal surfaces through its antibacterial and iron-binding properties. Human lactoferrin is found in colostrum and mature milk at levels of 2-5 g/1.
- Bovine lactoferrin shares 68% and 64% amino acid identity with human lactoferrin and murine lactoferrin, respectively.
- Lactoferricin is a pepsin-cleaved fragment of human and bovine lactoferrin. It has recently been found to contain the structural domain responsible for the bactericidal properties of lactoferrin (see e.g. Bellamy W., et al., Identification of the bactericidal domain of lac- toferrin, Biochim. Biophys.
- Lactoferrin receptors are found on many types of cells including monocytes and macrophages (Broxmeyer H.
- lactoferrin In addition to the role of lactoferrin as an essen- tial growth factor for both human B- and T-lymphocytic cell lines (see e.g. Hashizume S., et al., Identification of lactoferrin as an essential growth factor for human lymphocytic cell lines in serum-free medium, Biochem. Biophys. Acta 763:377-382, 1983) and as an inducer of growth of HT-29 cells (see e.g. Anuric M., et al., Effect of lactoferrin on the growth of a human colon adenocarci- noma cell line - comparison with transferrin.
- lactoferrin is a negative regulator of myelopoiesis (see e.g. Broxmeyer H. E., et al . , Specific- ity and modulation of the action of lactoferrin, a negative feedback regulator of myelopoiesis, Blood 55:324- 333, 1980, and Gentile P., et al., Suppression of mouse myelopoesis by administration of human lactoferrin in vivo and the comparative action of human transferrin, Blood 61:982-993, 1983). This latter function is mediated through suppression of IL-1 and GM-CSF release from ono- cytes and macrophages (see e.g.
- Lactoferrin acts on I-A and I-E/C antigen subpopulations of mouse peritoneal macrophages in the absence of T lymphocytes and other cell types to inhibit production of granulocyte-macrophage colony stimulatory factors "in vi- tro", J. Immunol. 133:306-314, 1984, and Zucali J. R. , et al., Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1, Blood 74:1531-1536, 1989).
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-1 interleukin-1
- IL-6 interleukin-6
- CSF colony- stimulating factor
- Such cells also have receptors for lactoferrin.
- An interaction between LPS and lactoferrin has been observed, the complex being bound to the cells also via LPS receptors (see Miyazawa K. , et al., Effect on lactoferrin binding to monocyte/macro- phage-differentiated HL-60 cells. J Immunol. 146:723-729, 1991) .
- lactoferrin exerted an inhibitory effect on the production of IL-1 and TNF- ⁇ in LPS stimulated monocytes (see Crouch P. M. , et al., Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin, Blood 80:235-240, 1992) .
- IL-6 response when added to fresh monocytes or cultured monocytic cells.
- lactoferrin and lactoferricin have an in vivo effect on all kinds of inflammation, i.e. not only when IL-6 is involved, as well as on infections, such as urinary tract infection, and tumours.
- an object of the present invention is to provide a pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tumours comprising an effective amount of lactoferrin and/or lactoferricin.
- Another object of the present invention is use of lactoferrin and/or lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tumours.
- a third object of the present invention is to pro- vide a method for treatment and/or prevention of infections, inflammations and/or tumours by administration of an effective amount of lactoferrin and/or lactoferricin.
- the pharmaceutical composition comprising an effective amount of lactoferrin and/or lactoferricin, is preferably administered systemically, and most preferably orally.
- the infections treatable with the pharmaceutical composition according to the present inventions include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc.
- Inflammation is a phenomenon marked by abnormal "redness” and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc. Inflammation is primarily caused by exposure to bacterial and other noxious agents and physical injury. Inflammation is mediated by a variety of cytoki- nes and other chemical signals. These mediators of inflammation include tumor necrosis factor- ⁇ (TNF- ⁇ ) , in- terleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and various colony-stimulating factors (CSFs) .
- TNF- ⁇ tumor necrosis factor- ⁇
- IL-1 in- terleukin-1
- IL-6 interleukin-6
- IL-8 interleukin-8
- CSFs colony-stimulating factors
- Prevention refers to minimizing, reducing or sup- pressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
- a “patient” is a subject at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition.
- An “effective amount” is an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious condition.
- Systemic administration can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramus- cular, subcutaneous, transdermal, suppositories
- the pharmaceutical composi- tion according to the present invention is formulated for oral administration.
- lactoferrin and lactoferricin used according to the present invention can e.g. be obtained through isola- tion and purification from natural sources, such as human milk, through use of genetic engineering techniques, such as recombinant expression or direct production in genetically altered animals, or through chemical synthesis.
- the lactoferricin can also be obtained by enzymatic degrada- tion of lactoferrin (hydrolysate) .
- the lactoferrin used according to the present invention is preferably human lactoferrin or bovine lactoferrin, and it is preferably administered as a hydrolysate.
- the lactoferricin used according to the present in- vention is preferably human lactoferricin or bovine lactoferricin.
- the pharmaceutical composition comprising lactoferrin and/or lactoferricin according to the present invention is particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by the fungus Candida albicans.
- the pharmaceutical composition according to the present invention is also well suited for preventive medical care by reducing the risk of developing urinary tract in- fection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications .
- the pharmaceutical composition according to the present invention may also comprise other components, such as pharmaceutically acceptable carriers, vehicles, preservatives, lubricators etc., which is well known to persons skilled in the art.
- pharmaceutically acceptable carriers such as pharmaceutically acceptable carriers, vehicles, preservatives, lubricators etc.
- lactoferrin and/or lactoferricin in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in pa- tients running an increased risk of such conditions due to an underlying disease or a medical treatment.
- lactoferrin and/or lactoferricin in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants.
- Fig. 1 a - d illustrate bacterial recovery from the kidney (a and b) and bladder (c and d) , respectively, of C3H/Tif and C3H/HeN mice infected with E. coli in the urinary tract and perorally given human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
- LF hum human lactoferrin
- LF bov bovine lactoferrin
- FIG. 3 a and b illustrate the kinetics of the urinary IL- 6 response in E. coli infected C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
- Fig. 3 a and b illustrate the kinetics of the urinary IL- 6 response in E. coli infected C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
- Fig. 3 a and b illustrate the kinetics of the urinary IL- 6 response in E. coli infected C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30
- FIG. 4 illustrates the serum IL-6 response 24 h after experimentally induced urinary tract infection in C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
- human lactoferrin LF hum
- bovine lactoferrin LF bov
- PBS PBS
- Fig. 5 illustrates the cytokine concentration in serum from mice with experimentally induced colitis after treatment with bovine lactoferrin (LF bov) compared to a control group not receiving lac- toferrin.
- LF bov bovine lactoferrin
- Example 1 Treatment of urinary tract infection in mice by oral administration of human lactoferrin
- lactoferrin The antibacterial and anti-inflammatory properties of lactoferrin were explored by studying the effects of lactoferrin given to mice (C3H/Tif and C3H/HeN) with experimentally induced urinary tract infection (UTI) .
- mice In order to induce urinary tract infection (UTI) in the mice, the animals were injected with 100 ⁇ l of a bac- terial solution containing 2xl0 9 E. coli-bacteria/ml diluted with phosphate-buffered saline (PBS) directly into the bladder via a catheter according to Svanborg-Eden et al (see C. Svanborg-Eden et al Infect. Immun. 55:1224- 1232, 1987). A solution containing 10 mg/ml of either human lactoferrin, bovine lactoferrin, or bovine lactoferricin was orally administered (50 ⁇ l) to the mice 30 min after the instillation of bacteria.
- PBS phosphate-buffered saline
- Urine samples from the mice were collected 0, 2, 5, and 24 hours after infection. 50 ⁇ l of each of the undiluted urine samples were cultured. The number of leucocytes in uncentrifuged urine was analyzed for each sample. The remaining urine from each animal at each sampling time was centrifuged and saved for IL-6 analysis. After 24 h the mice were bled and killed. The bladder and kidneys were taken out aseptically. The organs were homogenized, and serial dilutions thereof (bladder 1/1, 1/10, kidneys 1/1, 1/10, 1/100, 1/1000) were cultured on Drigalsky plates.
- a significant p value should be adjusted to p ⁇ 0.025 t illustrates a significant increase in the treatment group compared to the infected but untreated control group.
- I illustrates a significant decrease in the treatment group compared to the infected but untreated control group.
- lactoferrin both human and bovine significantly decreased the number of bacteria in the urinary tract of the infected mice, compared to the control group.
- Example 2 Treatment of experimental colitis by oral administration of human lactoferrin
- Acute colitis was induced in C57BI/6J mice by giving 5% dextransulphate in the drinking water for 6 days.
- Human lactoferrin was orally given to ten mice twice a day in a dose of 1 mg/mouse, starting from day 3 of the experiment.
- Two control groups (in total 17 mice) were given the same volume of drinking water or bovine serum albumin (BSA) (2 mg per mouse and day) .
- BSA bovine serum albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a pharmaceutical composition comprising lactoferrin and/or lactoferricin for treatment and/or prevention of infections, inflammations and/or tumours, to the use of lactoferrin and lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammmations and tumours, and to a method for treatment and/or prevention of infections, inflammations and/or tumours comprising administration of lactoferrin and/or lactoferricin. The invention is particularly well suited for treatment and/or prevention of urinary tract infections and colitis. The lactoferrin and/or lactoferricin according to the present invention is preferably orally administered. Furthermore, the composition comprising lactoferrin and/or lactoferricin may be included in an infant formula food.
Description
TREATMENT AND PREVENTION OF INFECTIONS, INFLAMMATIONS AND/OR TUMOURS WITH LACTOFERRIN AND/OR LACTOFERRICIN
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition comprising lactoferrin and/or lactoferricin for treatment and/or prevention of infections, inflamma- tions and/or tumours, to the use of lactoferrin and lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammations and tumours, and to a method for treatment and/or prevention of infections, inflammations and/or tu- mours comprising administration of lactoferrin and/or lactoferricin.
BACKGROUND OF THE INVENTION
It is known that human milk in several ways is anti- inflammatory. Goldman et al. pointed out that human milk is poor in initiators and mediators of inflammation but rich in anti-inflammatory agents (see Goldman A. S., et al., Anti-inflammatory properties of human milk, Acta Paediatr. Scand. 75 : 689-695, ' 1986) . Human milk contains several soluble anti-infective components, such as specific secretory IgA (SIgA) antibodies and non-specific components, including lactoferrin (LF) (see e.g. Hanson L. A., et al., Protective factors in milk and the development of the immune system, Pediatrics 75:172-176, 1983) .
Lactoferrin is a single chain metalbinding glycopro- tein with a molecular weight of 77 kd. It occurs in three isoforms: LF-α, LF-β, and LF-γ. These three variants have the same physical, chemical and antigenic characteris- tics, but differ in their functional properties.
The iron-binding lactoferrin is also present in specific granules of polymorphonuclear leucocytes and in other exocrine secretions than milk such as saliva, tears and bronchial mucus, as well as cervical secretion, amni- otic fluid, decidua, and trophoblasts (see e.g. Montreuil
J., et al., Isolement d'une lactosiderophiline du lait de femme, CR Acad. Sci. Paris 250 D: 1736-37, 1960; Montreuil J., et al., Preparation et proprietes de la lactosiderophiline (lactotransferrine) du fait de femme, Biochim. Biophys. Acta 45:413-421, 1960; and Masson P. L., et al., Lactoferrin an ironbinding protein neutrophilic leucocytes, J. Exp. Med. 130:643-656, 1969). Lactoferrin is associated with host defense at mucosal surfaces through its antibacterial and iron-binding properties. Human lactoferrin is found in colostrum and mature milk at levels of 2-5 g/1.
Bovine lactoferrin shares 68% and 64% amino acid identity with human lactoferrin and murine lactoferrin, respectively. Lactoferricin is a pepsin-cleaved fragment of human and bovine lactoferrin. It has recently been found to contain the structural domain responsible for the bactericidal properties of lactoferrin (see e.g. Bellamy W., et al., Identification of the bactericidal domain of lac- toferrin, Biochim. Biophys. Acta 1121:130-136, 1992, and Bellamy W., et al., Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin, J. Appl. Bact. 73:472-479, 1992). Lactoferrin receptors are found on many types of cells including monocytes and macrophages (Broxmeyer H. E., et al., Specificity and modulation of the action of lactoferrin, a negative feedback regulator of myelopoi- esis, Blood 55:324-333, 1980), lectin-stimulated human peripheral blood lymphocytes (Mazurier J., et al., Expression of human lactotransferrin receptors in phytohe- magglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by anti-ligand-affinity chromatography, Eur. J. Biochem. 179:481-487, 1989), brush-border cells (Hu W. L., et al., Lactotransferrin receptor of mouse small-intestinal brush border. Binding characteristics of membrane-bound and Triton X-100-
solubilized forms, Biochem. J. 249:435-441, 1988; Cox T. M., et al., Iron-binding proteins and influx of iron across the duodenal brush border. Evidence for specific lactotransferrin receptors in the human intestine. Bio- chim. Biophys. Acta 588:120-128, 1979; Mazurier J., et al., Visualization of lactotransferrin brush-border receptors by ligand-blotting. Biochim. Biophys. Acta 821:453-460, 1985; and Wei-Lu Hu, et al., Isolation and partial characterization of a lactotransferrin receptor from mouse intestinal brush-border, Biochemistry 29:535- 540, 1990), tumor cell lines, e.g. HT-29, HL-60, K562, (see e.g. Roiron D., et al., Lactoferrin-binding sites at the surface of HT29-D4 cells. Comparison with transfer- rin. Eur. J. Biochem. 186:367-373, 1989; Miyazawa K., et al . , Effect on lactoferrin binding to monocyte/macro- phage-differentiated HL-60 cells. J Immunol. 146:723-729, 1991; and Yamada Y., et al., Lactoferrin binding by leukemia cell lines, Blood 70:264-270, 1987).
In addition to the role of lactoferrin as an essen- tial growth factor for both human B- and T-lymphocytic cell lines (see e.g. Hashizume S., et al., Identification of lactoferrin as an essential growth factor for human lymphocytic cell lines in serum-free medium, Biochem. Biophys. Acta 763:377-382, 1983) and as an inducer of growth of HT-29 cells (see e.g. Anuric M., et al., Effect of lactoferrin on the growth of a human colon adenocarci- noma cell line - comparison with transferrin. In Vitro 20:543-548, 1984), lactoferrin is a negative regulator of myelopoiesis (see e.g. Broxmeyer H. E., et al . , Specific- ity and modulation of the action of lactoferrin, a negative feedback regulator of myelopoiesis, Blood 55:324- 333, 1980, and Gentile P., et al., Suppression of mouse myelopoesis by administration of human lactoferrin in vivo and the comparative action of human transferrin, Blood 61:982-993, 1983). This latter function is mediated through suppression of IL-1 and GM-CSF release from ono- cytes and macrophages (see e.g. Broxmeyer H. E., et al.,
Lactoferrin acts on I-A and I-E/C antigen subpopulations of mouse peritoneal macrophages in the absence of T lymphocytes and other cell types to inhibit production of granulocyte-macrophage colony stimulatory factors "in vi- tro", J. Immunol. 133:306-314, 1984, and Zucali J. R. , et al., Lactoferrin decreases monocyte-induced fibroblast production of myeloid colony-stimulating activity by suppressing monocyte release of interleukin-1, Blood 74:1531-1536, 1989). After binding of bacterial lipopolysaccharides (LPS) to macrophages, T-cells and cultured human monocytes, these cells synthesize tumor necrosis factor-α (TNF-α) , interleukin-1 (IL-1), interleukin-6 (IL-6), and colony- stimulating factor (CSF) (see e.g. Arai K. , et al., Cy- tokines: coordinators of immune and inflammatory responses, Ann. Rev. Biochem. 59:783-836, 1990; Hirano T., et al., Biological and clinical aspects of interleukin 6, Immunol. Today 11:443-449, 1990; and Shalaby M. R., et al., Endotoxin, tumor necrosis factor-α and interleukin-1 induce interleukin-6 production "in vivo", Clin. Immunol. Immunopath. 53:488-498, 1989). Cells participating in the inflammatory response carry several different LPS-binding receptors (Lei M-G., et al . , Specific endotoxic lipopoly- saccharide-binding proteins on murine splenocytes. II. Membrane localization and binding characteristics, J. Immunol. 141:1006-1011, 1988 and Couturier C, et al., Binding sites for endotoxin (LPS) on human monocytes, J. Immunol. 147:1899-1904, 19'91) . Such cells also have receptors for lactoferrin. An interaction between LPS and lactoferrin has been observed, the complex being bound to the cells also via LPS receptors (see Miyazawa K. , et al., Effect on lactoferrin binding to monocyte/macro- phage-differentiated HL-60 cells. J Immunol. 146:723-729, 1991) . Recently, it was showed that lactoferrin exerted an inhibitory effect on the production of IL-1 and TNF-α in LPS stimulated monocytes (see Crouch P. M. , et al., Regulation of cytokine release from mononuclear cells by
the iron-binding protein lactoferrin, Blood 80:235-240, 1992) .
It has earlier been shown (see Mattsby-Baltzer I. et al., Lactoferrin or a fragment thereof inhibits the endo- toxin-induced interleukin-6 response in human monocytic cells, Pediactric Research 40:257-262, 1996) that human and bovine lactoferrin as well as bovine lactoferricin suppress LPS-induced IL-6 response when added to fresh monocytes or cultured monocytic cells. Human lactoferrin has also been reported to suppress TNF-α induced
IL-6 response when added to fresh monocytes or cultured monocytic cells.
According to the present invention it has now been found that lactoferrin and lactoferricin have an in vivo effect on all kinds of inflammation, i.e. not only when IL-6 is involved, as well as on infections, such as urinary tract infection, and tumours.
DESCRIPTION OF THE INVENTION Thus, an object of the present invention is to provide a pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tumours comprising an effective amount of lactoferrin and/or lactoferricin. Another object of the present invention is use of lactoferrin and/or lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tumours.
A third object of the present invention is to pro- vide a method for treatment and/or prevention of infections, inflammations and/or tumours by administration of an effective amount of lactoferrin and/or lactoferricin.
The characterising features of the invention will be evident from the following description and the appended claims.
In order to treat a patient, suffering from an infection, an inflammation or a tumour, with the pharmaceu-
tical composition according to the invention, the pharmaceutical composition, comprising an effective amount of lactoferrin and/or lactoferricin, is preferably administered systemically, and most preferably orally. The infections treatable with the pharmaceutical composition according to the present inventions include infections caused by all kinds of pathogens, such as bacteria, viruses, fungi, etc.
Inflammation is a phenomenon marked by abnormal "redness" and swelling of tissues and organs, pain and heat in affected areas, capillary dilation, leucocyte infiltration, etc. Inflammation is primarily caused by exposure to bacterial and other noxious agents and physical injury. Inflammation is mediated by a variety of cytoki- nes and other chemical signals. These mediators of inflammation include tumor necrosis factor-α (TNF-α) , in- terleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), and various colony-stimulating factors (CSFs) . As used herein, "treatment" refers to preventing, curing, reversing, attenuating, alleviating, minimizing, suppressing or halting the deleterious effects of a disease state, disease progression or other abnormal condition, including urinary tract infections.
"Prevention" refers to minimizing, reducing or sup- pressing the risk of developing a disease state or progression or other abnormal or deleterious conditions.
A "patient" is a subject at risk for or suffering from a disease state, disease progression or other abnormal or deleterious condition. An "effective amount" is an amount sufficient to treat or prevent a disease state, disease progression or other abnormal or deleterious condition.
"Systemic administration" can be undertaken by oral, nasal, intravenous, intraartery, intracavitary, intramus- cular, subcutaneous, transdermal, suppositories
(including rectal) or other routes known to those of skill in the art. Preferably, the pharmaceutical composi-
tion according to the present invention is formulated for oral administration.
The lactoferrin and lactoferricin used according to the present invention can e.g. be obtained through isola- tion and purification from natural sources, such as human milk, through use of genetic engineering techniques, such as recombinant expression or direct production in genetically altered animals, or through chemical synthesis. The lactoferricin can also be obtained by enzymatic degrada- tion of lactoferrin (hydrolysate) .
The lactoferrin used according to the present invention is preferably human lactoferrin or bovine lactoferrin, and it is preferably administered as a hydrolysate. The lactoferricin used according to the present in- vention is preferably human lactoferricin or bovine lactoferricin.
The pharmaceutical composition comprising lactoferrin and/or lactoferricin according to the present invention is particularly well suited for treatment and/or prevention of urinary tract infection and colitis, but several other inflammatory and infectious diseases are also treatable according to the present invention, such as inflammatory bowel diseases, rheumatoid arthritis, conditions caused by the virus HIV-1, conditions caused by the virus CMV, and conditions caused by the fungus Candida albicans.
The pharmaceutical composition according to the present invention is also well suited for preventive medical care by reducing the risk of developing urinary tract in- fection or other inflammatory or infectious diseases in patients with an increased risk of attracting such complications .
The pharmaceutical composition according to the present invention may also comprise other components, such as pharmaceutically acceptable carriers, vehicles, preservatives, lubricators etc., which is well known to persons skilled in the art.
According to the present invention it is also possible to include lactoferrin and/or lactoferricin, in an effective amount, in any kind of food or beverage intended to reduce infections and/or inflammations in pa- tients running an increased risk of such conditions due to an underlying disease or a medical treatment.
According to the present invention it is also possible to include lactoferrin and/or lactoferricin, in an effective amount, in an infant formula food intended to inhibit harmful effects of bacteria, such as weight loss caused by inflammation induced by bacteria, viruses or fungi in infants.
EXAMPLES The invention will now be further explained in the following examples. These examples are only intended to illustrate the invention and should in no way be considered to limit the scope of the invention.
In the examples reference is made to the accompany- ing drawings on which:
Fig. 1 a - d illustrate bacterial recovery from the kidney (a and b) and bladder (c and d) , respectively, of C3H/Tif and C3H/HeN mice infected with E. coli in the urinary tract and perorally given human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria. The samples represented by symbols below the line were culture negative. Fig. 2 a and b illustrate the kinetics of the urinary leucocyte influx in E. coli infected C3H/Tif and
C3H/HeN mice treated with human lactoferrin (LF hum), bovine lactoferrin (LF bov), or PBS. Fig. 3 a and b illustrate the kinetics of the urinary IL- 6 response in E. coli infected C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
Fig. 4 illustrates the serum IL-6 response 24 h after experimentally induced urinary tract infection in C3H/Tif and C3H/HeN mice treated with human lactoferrin (LF hum) , bovine lactoferrin (LF bov) , or PBS, 30 min after the injection of bacteria.
Fig. 5 illustrates the cytokine concentration in serum from mice with experimentally induced colitis after treatment with bovine lactoferrin (LF bov) compared to a control group not receiving lac- toferrin.
Example 1: Treatment of urinary tract infection in mice by oral administration of human lactoferrin
The antibacterial and anti-inflammatory properties of lactoferrin were explored by studying the effects of lactoferrin given to mice (C3H/Tif and C3H/HeN) with experimentally induced urinary tract infection (UTI) .
In order to induce urinary tract infection (UTI) in the mice, the animals were injected with 100 μl of a bac- terial solution containing 2xl09 E. coli-bacteria/ml diluted with phosphate-buffered saline (PBS) directly into the bladder via a catheter according to Svanborg-Eden et al (see C. Svanborg-Eden et al Infect. Immun. 55:1224- 1232, 1987). A solution containing 10 mg/ml of either human lactoferrin, bovine lactoferrin, or bovine lactoferricin was orally administered (50 μl) to the mice 30 min after the instillation of bacteria.
Urine samples from the mice were collected 0, 2, 5, and 24 hours after infection. 50 μl of each of the undiluted urine samples were cultured. The number of leucocytes in uncentrifuged urine was analyzed for each sample. The remaining urine from each animal at each sampling time was centrifuged and saved for IL-6 analysis. After 24 h the mice were bled and killed. The bladder and kidneys were taken out aseptically. The organs were homogenized, and serial dilutions thereof (bladder
1/1, 1/10, kidneys 1/1, 1/10, 1/100, 1/1000) were cultured on Drigalsky plates.
The results are illustrated below in Table 1 and in Figures 1-4.
when four comparisons are made with one group, a significant p value should be adjusted to p<0.025 t illustrates a significant increase in the treatment group compared to the infected but untreated control group. I illustrates a significant decrease in the treatment group compared to the infected but untreated control group.
The data shown in Table 1 clearly shows the effect of the treatment with lactoferrin and lactoferricin.
From the table and the figures it is evident that orally administered lactoferrin (both human and bovine) significantly decreased the number of bacteria in the urinary tract of the infected mice, compared to the control group.
In Figures 2 a and b the kinetics of the urinary leucocyte influx is illustrated (** in Figure 2 a signi- fies p<0.01, Mann-Whitney test), and in Figure 3 a and b the IL-6 response in urine is illustrated (* in these figures signifies p<0.05, Mann-Whitney test). These figures clearly shows that the local inflammatory response was reduced after 24 h. The systemic cytokine response, viz. IL-6 response in serum, after 24 h is illustrated in Figure 4, and this response was also reduced in the lactoferrin treated animals.
In conclusion these results demonstrate that oral administration of lactoferrin or lactoferricin is sys- temically effective by preventing infection and inflammation in the urinary tract by an as yet unidentified mechanism.
Example 2: Treatment of experimental colitis by oral administration of human lactoferrin
Acute colitis was induced in C57BI/6J mice by giving 5% dextransulphate in the drinking water for 6 days. Human lactoferrin was orally given to ten mice twice a day in a dose of 1 mg/mouse, starting from day 3 of the experiment. Two control groups (in total 17 mice) were given the same volume of drinking water or bovine serum albumin (BSA) (2 mg per mouse and day) . 30% of the mice in the lactoferrin treated group presented gross rectal bleeding on day 5 and 6 compared to 100% in the control group (p = 0.0007, Fischer's test). Moreover, the colon length was significantly reduced in the control groups
compared with the lactoferrin treated group, indicating a more advanced inflammation of the colon tissue in the controls (p = 0.041, Mann-Whitney test). High concentrations of lactoferrin were found in serum of the lactofer- rin treated group.
In an other experiment using 3% dextransulphate the systemic TNF-α response was reduced in the lactoferrin treated mice after 10 days (p < 0.0006). The result is illustrated in Figure 5. In summary, the results demonstrate that oral administration of LF reduces some of the clinical symptoms of experimental colitis.
Claims
1. A pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tumours comprising an effective amount of lactoferrin and/or lactoferricin.
2. A pharmaceutical composition according to claim 1 intended for oral administration.
3. A pharmaceutical composition according to claim 1 or claim 2, intended for treatment and/or prevention of urinary tract infection.
4. A pharmaceutical composition according to claim 1 or claim 2, intended for treatment and/or prevention of colitis .
5. A pharmaceutical composition according to any one of claims 1-4, wherein the lactoferrin and/or the lactoferricin is derived from a human or bovine source.
6. A pharmaceutical composition according to any one of claims 1-5, wherein the lactoferrin is included in the pharmaceutical composition as a hydrolysate.
7. An infant formula food comprising the pharmaceutical composition according to any one of claims 1-6.
8. Use of lactoferrin and/or lactoferricin in the production of a pharmaceutical composition for treatment and/or prevention of infections, inflammations and/or tu- ours.
9. Use of lactoferrin and/or lactoferricin according to claim 8, wherein the pharmaceutical composition is intended for oral administration.
10. Use of lactoferrin and/or lactoferricin accord- ing to claim 8 or claim 9, wherein the pharmaceutical composition is intended for treatment and/or prevention of urinary tract infection.
11. Use of lactoferrin and/or lactoferricin according to claim 8 or claim 9, wherein the pharmaceutical composition is intended for treatment and/or prevention of colitis.
12. Use of lactoferrin and/or lactoferricin according to any one of claims 8-11, wherein the lactoferrin and/or the lactoferricin is derived from a human or bovine source.
13. Use of lactoferrin according to any one of claims 8-12, wherein the lactoferrin is included in the pharmaceutical composition as a hydrolysate.
14. Use of lactoferrin and/or lactoferricin according to any one of claims 8-13, wherein the pharmaceutical composition constitutes or is included in an infant formula food.
15. A method for treatment and/or prevention of infections, inflammations and/or tumours whereby an effective amount of a substance chosen from the group consist- ing of lactoferrin and lactoferricin is administered to a patient.
16. A method according to claim 15, wherein the substance is orally administered.
17. A method according to claim 15 or claim 16, used for treatment and/or prevention of urinary tract infection.
18. A method according to claim 15 or claim 16, used for treatment and/or prevention of colitis.
19. A method according to any one of claims 15-18, wherein the lactoferrin and/or the lactoferricin is derived from a human or bovine source.
20. A method according to any one of claims 15-19, wherein the lactoferrin is used in the form of a hydrolysate.
21. A method according to any one of claims 15-20, wherein the substance is included in an infant formula food.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2376196P | 1996-08-12 | 1996-08-12 | |
| US23761P | 1996-08-12 | ||
| PCT/SE1997/001344 WO1998006425A1 (en) | 1996-08-12 | 1997-08-12 | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0920331A1 true EP0920331A1 (en) | 1999-06-09 |
Family
ID=21817049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP97935939A Withdrawn EP0920331A1 (en) | 1996-08-12 | 1997-08-12 | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0920331A1 (en) |
| JP (1) | JP2001504447A (en) |
| AU (1) | AU3872797A (en) |
| CA (1) | CA2263416A1 (en) |
| WO (1) | WO1998006425A1 (en) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0980261A4 (en) * | 1997-05-03 | 2003-04-23 | Univ Texas | METHODS OF PREVENTING AND TREATING INSULATE INDUCED METABOLIC IMBALANCE IN HUMANS AND ANIMALS |
| SE9804614A0 (en) * | 1998-07-06 | 2000-01-07 | A+ Science Invest Ab | New peptides and use thereof |
| GB9818938D0 (en) * | 1998-08-28 | 1998-10-21 | Alpharma As | Bioactive peptides |
| US8283315B2 (en) | 1998-08-28 | 2012-10-09 | Lytix Biopharma As | Inhibition of tumour growth |
| GB0005702D0 (en) * | 2000-03-09 | 2000-05-03 | Alpharma As | Method |
| JP4683740B2 (en) * | 2001-02-15 | 2011-05-18 | 明治乳業株式会社 | Relieving symptoms associated with inflammation |
| US20030191193A1 (en) * | 2002-04-03 | 2003-10-09 | Jillian Cornish | Lactoferrin |
| EP1499341A4 (en) * | 2002-04-18 | 2010-10-27 | Univ Iowa Res Found | PROCESS FOR INHIBITING AND PROCESSING BIOLOGICAL FILMS USING METAL CHELATORS |
| US20040082504A1 (en) | 2002-05-10 | 2004-04-29 | Atul Varadhachary | Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| GB0229658D0 (en) * | 2002-12-20 | 2003-01-22 | Cleeve Richard J | Bird feed |
| JP2007524654A (en) | 2003-06-06 | 2007-08-30 | エイジェニックス インコーポレイテッド | Lactoferrin as an adjuvant in cancer vaccines |
| SE528337C2 (en) * | 2004-06-23 | 2006-10-24 | Nestor Medical Ab | Composition comprising lactic acid and lactoferrin, or a peptide fragment thereof, and use of this composition for treating conditions in the urogenital system |
| WO2006047744A2 (en) | 2004-10-26 | 2006-05-04 | Agennix Incorporated | Compositions of lactoferrin related peptides and uses thereof |
| JP5872131B2 (en) * | 2006-11-29 | 2016-03-01 | ロート製薬株式会社 | Antifungal pharmaceutical composition |
| EP2050461A1 (en) | 2007-10-19 | 2009-04-22 | PharmaSurgics in Sweden AB | Peptides based on the sequence of human lactoferrin and their use |
| EP2060586A1 (en) | 2007-11-14 | 2009-05-20 | PharmaSurgics in Sweden AB | New synthetic arginine substituted peptides and their use |
| JP2011051914A (en) * | 2009-08-31 | 2011-03-17 | Obihiro Univ Of Agriculture & Veterinary Medicine | Intestinal inflammation inhibitor including pasteurized whey protein concentrate |
| JP5177901B2 (en) * | 2009-12-02 | 2013-04-10 | 株式会社明治 | Nutritional composition |
| US20120171328A1 (en) * | 2011-01-05 | 2012-07-05 | Dattatreya Banavara | Composition comprising heat labile milk proteins and process for preparing same |
| EP2481751A1 (en) | 2011-01-26 | 2012-08-01 | PharmaSurgics in Sweden AB | Human lactoferrin derived peptides |
| JP5763024B2 (en) * | 2012-09-07 | 2015-08-12 | 株式会社明治 | Nutritional composition |
| ITMI20122152A1 (en) | 2012-12-17 | 2014-06-18 | Progine Farmaceutici S R L | COMPOSITION FOR TOPICAL USE. |
| EP2992894A1 (en) | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Vaginal formulations for preventing and treating vaginal and cervico-vaginal infections |
| WO2016056665A1 (en) * | 2014-10-08 | 2016-04-14 | 学校法人慶應義塾 | White blood cell extracellular trap formation inhibitor |
| WO2021222584A2 (en) * | 2020-04-29 | 2021-11-04 | The Regents Of The University Of Michigan | Inhibition of sars-cov-2 viral entry through administration of lactoferrin and uses thereof |
| CN116036054B (en) * | 2023-03-07 | 2024-04-26 | 湖北嫦娥生物股份有限公司 | Lactoferrin patch and application thereof in preparation of postoperative rehabilitation drugs for tumor patients |
| CN116327740B (en) * | 2023-03-07 | 2024-07-02 | 苏州青珩信息科技有限公司 | A lactoferrin patch and its use in preparing a drug for treating recurrent respiratory tract infections in children |
| EP4523699A1 (en) * | 2023-09-15 | 2025-03-19 | FB Dermo srl | Anti-inflammatory dermatological composition comprising glycerophosphoinositol, a lactoferrin hydrolysate and a cannabinoid, in particular for treating seborrheic dermatitis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402789B (en) * | 1991-03-25 | 1997-08-25 | Immuno Ag | PHARMACEUTICAL PREPARATION BASED ON PLASMA PROTEINS |
| AU665381B2 (en) * | 1992-01-23 | 1996-01-04 | Morinaga Milk Industry Company Limited | Antibacterial agent and treatment of article therewith |
| JPH06145068A (en) * | 1992-04-02 | 1994-05-24 | Imuno Japan:Kk | Biophylaxis enhancer, medicine for improvement of infectious disease and biophylaxis enhancing food |
| JPH08217693A (en) * | 1995-02-17 | 1996-08-27 | Yoshihisa Naito | New medicine composition |
| IT1278137B1 (en) * | 1995-07-12 | 1997-11-17 | Piera Valenti | USE OF LACTOFERRIN FOR THE TOPICAL THERAPY OF ACUTE OR RECURRENT INFECTIONS CAUSED BY "STREPTOCOCCUS PYOGENES" OR OTHERS |
| WO1997005884A1 (en) * | 1995-08-07 | 1997-02-20 | New England Medical Center Hospitals, Inc. | Infant formula and infant formula additives |
-
1997
- 1997-08-12 EP EP97935939A patent/EP0920331A1/en not_active Withdrawn
- 1997-08-12 AU AU38727/97A patent/AU3872797A/en not_active Abandoned
- 1997-08-12 JP JP50964098A patent/JP2001504447A/en active Pending
- 1997-08-12 WO PCT/SE1997/001344 patent/WO1998006425A1/en not_active Application Discontinuation
- 1997-08-12 CA CA002263416A patent/CA2263416A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| See references of WO9806425A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2263416A1 (en) | 1998-02-19 |
| JP2001504447A (en) | 2001-04-03 |
| WO1998006425A1 (en) | 1998-02-19 |
| AU3872797A (en) | 1998-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998006425A1 (en) | Treatment and prevention of infections, inflammations and/or tumours with lactoferrin and/or lactoferricin | |
| Egea et al. | GM-CSF produced by nonhematopoietic cells is required for early epithelial cell proliferation and repair of injured colonic mucosa | |
| Broide et al. | Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice | |
| Finotto et al. | Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo | |
| Conti et al. | Cultures of astrocytes and microglia express interleukin 18 | |
| Ginkel et al. | Partial IgA-deficiency with increased Th2-type cytokines in TGF-β1 knockout mice | |
| Ogawa et al. | Regulated production of the chemokine CCL28 in human colon epithelium | |
| Fu et al. | The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF. | |
| KR100297959B1 (en) | Treatment of HIV-serum-positive individuals with whey protein | |
| Inoue et al. | Composition and physiological functions of the porcine colostrum | |
| IL129211A (en) | Use of colostrinin in the manufacture of a medicament for the treatment of central nervous system disorders | |
| Crocker et al. | Regulation of a murine macrophage haemagglutinin (sheep erythrocyte receptor) by a species-restricted serum factor | |
| Bodammer et al. | Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin | |
| JP4668534B2 (en) | Enamel matrix protein composition for modulating immune response | |
| Dupont | Donor milk compared with mother’s own milk | |
| JPH06503320A (en) | Use of protective agents against reactivated oxygen species | |
| Yanagi et al. | In VivoRole of IL-10 and IL-12 during Development of Sjögren's Syndrome in MRL/lprMice | |
| Appel et al. | Sub-chronic (13-week) oral toxicity study in rats with recombinant human lactoferrin produced in the milk of transgenic cows | |
| EP0950416B1 (en) | Use of TCF-II for the treatment of cancer related body weight loss, anaemia and TNF elevation | |
| US6613741B2 (en) | Method for treating aseptic SIRS in humans and other animals | |
| Toft et al. | Effect of hemodiafiltration and sepsis on chemotaxis of granulocytes and the release of IL‐8 and IL‐10 | |
| JP4787445B2 (en) | Antigen-specific IgE antibody production inhibitor | |
| AU732053B2 (en) | Agents for the prevention and/or treatment of radiation-induced disorders | |
| Ohtsuka et al. | Changes in mRNA of immune factors expressed by milk somatic cells of Holstein cows with hypocalcemia after calving | |
| Faist et al. | Posttraumatic immune suppression as initiator of organ failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 19990202 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
| 18W | Application withdrawn |
Withdrawal date: 20000630 |